{
  "drug_name": "Cefmetazole",
  "tradename": "Zefazone",
  "usage_and_dosing": {
    "general": [
      "Cefmetazole is a second-generation semisynthetic parenteral cephamycin.",
      "Resistant in vitro to hydrolysis by ESBL-producing Enterobacterales.",
      "Contains an N-methyl-tetrazole-thiol side chain, which inhibits vitamin K epoxide reductase and may inhibit synthesis of vitamin K-dependent coagulation factors.",
      "Not available in the US but often used in Japan, Taiwan, and China.",
      "Possible carbapenem-sparing alternative (where available) for ESBL-producing Enterobacterales infection: Open Forum Infect Dis 2023;10:ofad502; Antimicrob Agents Chemother 2023;67:e0051023.",
      "Good overview: Pharmacotherapy 1991;11:2-19."
    ],
    "adult_dose": {
      "urinary_tract_infection": "2 gm IV q12h",
      "mild_to_moderate_infection": "2 gm IV q8h",
      "severe_to_life_threatening_infection": "2 gm IV q6h"
    },
    "pediatric_dose": {
      "dose_age_gt_28_days": "Safety and efficacy not established",
      "max_day": "-"
    }
  },
  "renal_adjustment": {
    "half_life_normal": "1-1.5",
    "half_life_esrd": "29",
    "dose_renal_function_normal": "2 gm IV q8-12h",
    "crcl_or_egfr": "CrCl >90: No dosage adjustment. CrCl 50-90: 1-2 gm q12h. CrCl 30-49: 1 gm q12h. CrCl 10-29: 1-2 gm q24h. CrCl <10: 1-2 gm q48h",
    "hemodialysis": "1-2 gm q48h (AD on dialysis days)",
    "capd": "No data",
    "crrt": "No data",
    "sled": "No data"
  },
  "hepatic_adjustment": {
    "mild_impairment_child_pugh_a": "No dosage adjustment",
    "moderate_impairment_child_pugh_b": "No dosage adjustment",
    "severe_impairment_child_pugh_c": "No dosage adjustment"
  },
  "adverse_effects": [
    "Gastrointestinal (nausea, vomiting, diarrhea)",
    "Potential for C. difficile infection",
    "Hypersensitivity reactions",
    "Increased LFTs",
    "Disulfiram-like reaction",
    "Coagulopathy"
  ],
  "pregnancy_risk": {
    "fda_risk_category": "No evidence of toxicity in humans or animals",
    "lactation": "No data",
    "footnote": "Capital letter = Old FDA risk category; Text = New FDA risk category"
  },
  "antimicrobial_spectrum": {},
  "pharmacology": {
    "pk_pd_index": "T>MIC",
    "preparations": "Injection",
    "food_recommendation": null,
    "oral_absorption_percent": null,
    "tmax_hr": null,
    "peak_serum_conc_ug_ml": "143 (2 gm IV, SD)",
    "peak_urine_conc_ug_ml": ">2000 (2 gm IV, SD)",
    "protein_binding_percent": "65-85",
    "volume_of_distribution_vd_l_kg": "≈ 0.18 L/kg",
    "avg_serum_half_life_hr": "1.1-1.5",
    "elimination": "Renal",
    "bile_penetration_percent": "No data",
    "csf_blood_percent": "No data",
    "therapeutic_levels_in_csf": "No data",
    "auc_ug_hr_ml": "161 (2 gm IV, 0-inf)"
  },
  "enzyme_transporter_mediated_interactions": {
      "cyp450s_substrate": [],
      "transporters_substrate": ["OAT1", "OAT3"],
      "ugts_substrate": [],
      "cyp450s_inhibited": [],
      "transporters_inhibited": [],
      "ugts_inhibited": [],
      "cyp450s_induced": [],
      "transporters_induced": [],
      "ugts_induced": [],
      "impact_on_serum_drug_concentrations": "None expected"
  },
  "major_drug_interactions": [
      {
          "drug": "Probenecid",
          "effect": "↑ cefmetazole",
          "management": "Monitor, adjust dosage"
      }
  ]
}
